Deals & Corporate Governance

  • February 13, 2026

    CareDx Seeks High Court Review Of $45M False Ad Case

    Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.

  • February 11, 2026

    Ventas, Welltower See Growth Amid Senior Housing Push

    Real estate investment trusts Welltower Inc. and Ventas Inc. recorded strong financial results from the last quarter and the full year of 2025, as both companies intensified their focus on senior housing, a sector where they expect to see skyrocketing demand due to demographic trends.

  • February 10, 2026

    Judge Limits Insurers' Exposure in Opioid Coverage Fight

    Insurers garnered several wins Tuesday in a dispute over coverage for thousands of opioid suits against bankrupt pharmaceutical company Endo International, with a Pennsylvania federal court ruling favorably for the carriers on the interpretation of claims-made provisions and the meaning of "damages for bodily injury."

  • February 10, 2026

    This Week's Healthcare Earnings: Lilly, Cigna And More

    About a dozen major healthcare companies have posted year-end results and issued 2026 guidance in recent days, including major names like Eli Lilly, Cigna and CVS. Here's what you need to know from earnings reports this past week.

  • February 09, 2026

    5th Circ. Tosses Challenge To La. 340B Discount Drug Rule

    A Fifth Circuit panel upheld on Monday a Louisiana law that allows the state to stop prescription drug manufacturers from blocking safety-net healthcare providers from contracting with outside pharmacies to dispense discounted medicines under the federal 340B Discount Drug program. 

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    Colo. Nonprofit Drops Suit Over Medicaid Therapy Cuts

    A Colorado healthcare nonprofit Thursday voluntarily dismissed its complaint seeking to reverse an allegedly unlawful executive order signed by Gov. Jared Polis that cut state Medicaid spending to pediatric behavioral therapy and autism therapy services. 

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    NJ Watchdog Must Give Up Files In Hospital Row

    A New Jersey federal judge has refused to disturb a magistrate judge's decision compelling a state watchdog to turn over documents from its inquiry into CarePoint Health Systems Inc., rejecting the agency's bid to shield its files with grand-jury-like secrecy and reaffirming that federal privilege law governs discovery disputes in federal court.

  • February 06, 2026

    2nd Circ. Affirms Nix Of NY Anesthesiologists' Antitrust Suit

    A New York anesthesiology practice didn't sustain an antitrust injury when a UnitedHealthcare unit used its market power to cut reimbursement rates, a Second Circuit panel affirmed Friday, finding that the change in rates was a natural consequence of the health insurance system and doesn't equate to anticompetitive harm. 

  • February 05, 2026

    Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'

    Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day. 

  • February 05, 2026

    Covington, Davis Polk Lead Eikon's Upsized $381M IPO

    Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.

  • February 04, 2026

    Hartford HealthCare Must Provide Docs On $86M Takeovers

    Hartford HealthCare Corp. must hand over internal documents detailing its $86.1 million acquisitions of two hospitals from bankrupt Prospect Medical to a group of plaintiffs who accuse the health system of trying to create a monopoly for inpatient hospital services, a Connecticut state court judge has ruled.

  • February 04, 2026

    Ga. Justices Uphold $8.3M Verdict In MedMal Case

    The Georgia Supreme Court said it won't disturb a $6.5 million verdict or an additional $1.8 million attorney fee award in a suit over a botched knee surgery, with one justice clarifying what courts can do regarding jury instructions in medical malpractice cases.

  • February 04, 2026

    2nd Circ. Backs Block On Hundreds Of Geico Collection Cases

    The Second Circuit found no error in a preliminary injunction pausing over 600 collection actions filed against Geico by a doctor and medical practice accused by the insurer of a scheme to exploit New York's no-fault automobile insurance laws.

  • February 03, 2026

    This Week's Healthcare Earnings: Novo, Elevance And More

    More than half a dozen healthcare companies posted earnings this week, including big names like Pfizer, Elevance and Roche. Here's what you need to know from earnings this week.

  • February 03, 2026

    Biopharma Co.'s Down-Round IPO May Signal More To Come

    Biotech Eikon Therapeutics is preparing for a down-round IPO experts say may serve as a bellwether for how certain life sciences companies get valued in public markets.

  • February 03, 2026

    2nd Circ. Skeptical Anesthesia Group Suffered Antitrust Harm

    A Second Circuit panel seemed poised Tuesday to find that an anesthesiology practice didn't suffer an antitrust injury in its claim that a United Healthcare unit used its market power in New York to cut reimbursement rates.

  • January 30, 2026

    SelectQuote Execs Face Investor Suit Over Kickback Probe

    Executives and directors of insurance comparison platform SelectQuote were hit with a shareholder's derivative suit accusing them of concealing a kickback scheme currently subject of a False Claims Act suit by the U.S. Department of Justice.

  • January 28, 2026

    Biogen Can't Escape Amended Antitrust Suit Over MS Drug

    Biogen Inc. must face health plans' claims that it bribed pharmacy benefit managers to stifle generics competition for its multiple sclerosis drug Tecfidera, after an Illinois federal judge found Wednesday that the plans' latest amended complaint in their consolidated antitrust litigation corrects her prior concerns with the pleadings.

  • January 28, 2026

    Fla. Court Undoes Class Cert. Of Medicare Cos. In USAA Suit

    A Florida state appeals court on Wednesday reversed class certification for a group of Medicare-contracted businesses suing USAA Casualty Insurance Co. over allegations the insurer sidestepped its obligation to pay automobile injury claims and passed them on to so-called secondary payers. 

  • January 27, 2026

    This Week's Healthcare Earnings: UnitedHealth, HCA, J&J

    It was a week of good news and bad news for the healthcare industry. Earnings season kicked off when three companies posted financials for the final three months of last year, and results were mixed. Here's what you need to know about the developments.

  • January 27, 2026

    Biotech Fundraising A Good Sign For Public Markets

    At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.

  • January 26, 2026

    Healthcare Group Of The Year: Holland & Knight

    Holland & Knight LLP attorneys advised AdventHealth on its multimillion-dollar outpatient acquisitions, Evernorth Health Services' $3.5 billion investment in Shields Health Solutions and Palomar Health on its strategic partnership with the University of California San Diego, earning it a spot among the 2025 Law360 Healthcare Groups of the Year.

Expert Analysis

  • ESG Around The World: Singapore

    Author Photo

    Singapore is keen to establish itself as a leading international financial center and a key player in the sustainable finance ecosystem, and key initiatives led by its government and other regulatory bodies have helped the Asian nation progress from its initially guarded attitude toward ESG investment and reporting, say attorneys at Morgan Lewis.

  • The Pop Culture Docket: Judge D'Emic On Moby Grape

    Author Photo

    The 1968 Moby Grape song "Murder in My Heart for the Judge" tells the tale of a fictional defendant treated with scorn by the judge, illustrating how much the legal system has evolved in the past 50 years, largely due to problem-solving courts and the principles of procedural justice, says Kings County Supreme Court Administrative Judge Matthew D'Emic.

  • Navigating Asset Tracing Challenges In Bankruptcy

    Author Photo

    A Virginia court’s recent ruling in Health Diagnostic Laboratory Inc.'s bankruptcy highlights the heightened demand for asset tracing and the strategic use of the lowest intermediate balance rule in recovering funds from commingled accounts, says Daniel Lowenthal at Patterson Belknap.

  • Performing Music Makes Me A Better Lawyer

    Author Photo

    The discipline of performing live music has directly and positively influenced my effectiveness as a litigator — serving as a reminder that practice, intuition and team building are all important elements of a successful law practice, says Jeff Wakolbinger at Bryan Cave.

  • 'Patient' Definition Ruling Raises Discount Drug Questions

    Author Photo

    A South Carolina federal court's recent decision in Genesis Health Care v. Becerra supports a broader definition of a "patient" eligible to receive discounted drugs under the Section 340B program, but raises a host of novel questions regarding how the decision will affect covered entities and enforcement actions, say attorneys at McDermott.

  • Breaking Down High Court's New Code Of Conduct

    Author Photo

    The U.S. Supreme Court recently adopted its first-ever code of conduct, and counsel will need to work closely with clients in navigating its provisions, from gift-giving to recusal bids, say Phillip Gordon and Mateo Forero at Holtzman Vogel.

  • Legal Profession Gender Parity Requires Equal Parental Leave

    Author Photo

    To truly foster equity in the legal profession and to promote attorney retention, workplaces need to better support all parents, regardless of gender — starting by offering equal and robust parental leave to both birthing and non-birthing parents, says Ali Spindler at Irwin Fritchie.

  • Activist Short-Sellers Are The Dark Knights Of Wall Street

    Author Photo

    While so-called activist short-sellers have been subject to increased scrutiny in recent years, these investors work in the shadows like Batman to expose fraud on Wall Street, often generating leads that may move regulators to take action, say attorneys at Labaton Sucharow.

  • Writing Thriller Novels Makes Me A Better Lawyer

    Author Photo

    Authoring several thriller novels has enriched my work by providing a fresh perspective on my privacy practice, expanding my knowledge, and keeping me alert to the next wave of issues in an increasingly complex space — a reminder to all lawyers that extracurricular activities can help sharpen professional instincts, says Reece Hirsch at Morgan Lewis.

  • What Lawyers Must Know About Calif. State Bar's AI Guidance

    Author Photo

    Initial recommendations from the State Bar of California regarding use of generative artificial intelligence by lawyers have the potential to become a useful set of guidelines in the industry, covering confidentiality, supervision and training, communications, discrimination and more, say attorneys at Debevoise.

  • Industry Must Elevate Native American Women Attys' Stories

    Author Photo

    The American Bar Association's recent research study into Native American women attorneys' experiences in the legal industry reveals the glacial pace of progress, and should inform efforts to amplify Native voices in the field, says Mary Smith, president of the ABA.

  • Understanding Discovery Obligations In Era Of Generative AI

    Excerpt from Practical Guidance
    Author Photo

    Attorneys and businesses must adapt to the unique discovery challenges presented by generative artificial intelligence, such as chatbot content and prompts, while upholding the principles of fairness, transparency and compliance with legal obligations in federal civil litigation, say attorneys at King & Spalding.

  • Employer Lessons After 2023's Successful Labor Strikes

    Author Photo

    Following recent historic strikes in the automotive, entertainment and health care industries, employers of all types can learn key insights about how unions may approach negotiations and strikes going forward, and nonunionized workplaces should anticipate a drive for increased union membership, say Lenny Feigel and Mark Neuberger at Foley & Lardner.